Q1 2026 Bio-Techne Corp Earnings Call Transcript

Nov 5, 2025 / 02:00 PM GMT

Release Date Price: $59.94 (-1.90%)

Transcript 10-Q8-K

Key Points

Positve

Bio-Techne Corp (TECH) achieved a 90 basis point year-over-year increase in adjusted operating margin, reaching 29.9%, reflecting strong cost management and productivity focus.
The company reported robust demand from large pharma customers, with low double-digit growth, indicating continued interest in their tools and technologies.
China delivered its second consecutive quarter of growth, driven by strong performance in the proteins simple analytical instruments and spatial biology portfolio.
Bio-Techne Corp (TECH) is seeing early signs of stabilization in biotech activity levels, supported by increased M&A activity and favorable licensing trends.
The company is advancing innovation with the upcoming launch of an ultra-sensitive cartridge for the Simple Flex Amino Assay platform, promising significant improvements in biomarker detection.

Negative

Bio-Techne Corp (TECH) experienced a 1% decline in organic revenue, primarily due to clinical stage timing issues with large customers in the cell therapy business.
The biotech funding environment remains challenging, impacting spending behavior and resulting in high single-digit declines in Q1.
The US academic market saw a modest decline, although there were signs of improvement as the quarter progressed.
Revenue in North America declined mid-single-digits, affected by order timing in cell therapy and continued funding pressure in biotech.
The diagnostics and spatial biology segment saw a 4% year-over-year decline in sales, impacted by the exosome diagnostics divestiture.

Refinitiv StreetEvents Event Transcript
P R E L I M I N A R Y V E R S I O N

TECH.OQ - Bio-Techne Corp
Q1 2026 Bio-Techne Corp Earnings Call
Nov 05, 2025 / 02:00PM GMT

=====================
Conference Call Participants
=====================
* >>NOTE
* >>Transcription Start

=====================
Presentation
--------------------------------------------------------------------------------
>>NOTE [1]
--------------------------------------------------------------------------------

THIS TRANSCRIPT IS THE INITIAL PRELIMINARY VERSION WHICH LEVERAGES MACHINE LEARNING TECHNOLOGY. AS SUCH, PLEASE BE AWARE THERE MAY BE INACCURACIES IN THE TEXT DISPLAYED. FUTURE EDITED VERSIONS WILL BE REVIEWED FOR GREATER ACCURACY.

--------------------------------------------------------------------------------
>>Transcription Start, [2]
--------------------------------------------------------------------------------

Thank you for your continued patience.

Your meeting will begin shortly.

Good morning and welcome to the

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.